Barinthus Biotherapeutics (BRNS) News Today $1.04 +0.12 (+12.68%) (As of 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Barinthus Biotherapeutics Appoints New Chief Scientific OfficerNovember 27, 2024 | markets.businessinsider.comBarinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific OfficerNovember 25, 2024 | globenewswire.comPromising Clinical Trials and Potential Functional Cure Drive Buy Rating for Barinthus BiotherapeuticsNovember 19, 2024 | markets.businessinsider.comPromising New Data from Hepatitis B Trial by Arbutus and BarinthusNovember 17, 2024 | msn.comArbutus and Barinthus announce new data from IM-PROVE II trialNovember 16, 2024 | markets.businessinsider.comBarinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb SeroconversionNovember 15, 2024 | globenewswire.comArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BNovember 15, 2024 | globenewswire.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest UpdateBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 8,400 shares, a growth of 110.0% from the October 15th total of 4,000 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 29,500 shares, the short-interest ratio is currently 0.3 days.November 13, 2024 | marketbeat.comWilliam Blair Has Positive Estimate for BRNS FY2024 EarningsBarinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Research analysts at William Blair boosted their FY2024 earnings per share estimates for shares of Barinthus Biotherapeutics in a research note issued on Wednesday, November 6th. William Blair analyst A. Hsieh now forecasts that the compNovember 11, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Barinthus Biotherapeutics (NASDAQ:BRNS)HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday.November 8, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Posts Earnings Results, Beats Estimates By $0.23 EPSBarinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.23. The business had revenue of $14.97 million for the quarter. During the same period in the prior year, the company earned ($0.37) earnings per share.November 7, 2024 | marketbeat.comBarinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial ResultsNovember 6, 2024 | globenewswire.comBarinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November ConferencesOctober 31, 2024 | markets.businessinsider.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 13.0%Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 4,000 shares, a decline of 13.0% from the September 30th total of 4,600 shares. Based on an average trading volume of 29,200 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.October 29, 2024 | marketbeat.comBarinthus Bio gets Buy stock rating on trial progressOctober 4, 2024 | investing.comBarinthus Bio retains Buy rating from H.C. Wainwright with trial startSeptember 28, 2024 | uk.investing.comBarinthus Biotherapeutics: Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseSeptember 24, 2024 | finanznachrichten.deBarinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac DiseaseSeptember 24, 2024 | finance.yahoo.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Drop in Short InterestBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 5,800 shares, a decrease of 40.2% from the August 15th total of 9,700 shares. Based on an average daily volume of 24,300 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are sold short.September 14, 2024 | marketbeat.com1,513,644 Shares in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Purchased by Alphabet Inc.Alphabet Inc. bought a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,513,644 shares of the companySeptember 3, 2024 | marketbeat.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Large Decline in Short InterestBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 9,700 shares, a decrease of 34.5% from the July 31st total of 14,800 shares. Approximately 0.0% of the company's stock are short sold. Based on an average daily volume of 23,800 shares, the short-interest ratio is currently 0.4 days.August 29, 2024 | marketbeat.comResearch Analysts Offer Predictions for Barinthus Biotherapeutics plc's Q3 2024 Earnings (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Investment analysts at HC Wainwright cut their Q3 2024 earnings per share estimates for shares of Barinthus Biotherapeutics in a research note issued on Monday, August 12th. HC Wainwright analyst Y. Chen now expects that the company willAugust 15, 2024 | marketbeat.comM&G Plc Invests $7.28 Million in Barinthus Biotherapeutics plc (NASDAQ:BRNS)M&G Plc bought a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,197,349 shares of the company's stock, vAugust 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $9.50 Price Target at Alliance Global PartnersAlliance Global Partners reduced their target price on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a "buy" rating for the company in a research note on Tuesday.August 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSBarinthus Biotherapeutics (NASDAQ:BRNS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.01).August 11, 2024 | marketbeat.comBarinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial ResultsAugust 8, 2024 | stockhouse.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Increases By 223.9%Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 29,800 shares, an increase of 223.9% from the June 30th total of 9,200 shares. Based on an average trading volume of 24,300 shares, the short-interest ratio is presently 1.2 days. Currently, 0.1% of the company's shares are sold short.July 25, 2024 | marketbeat.comHere's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn SituationJuly 24, 2024 | finance.yahoo.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Increase in Short InterestBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 7,200 shares, an increase of 24.1% from the May 31st total of 5,800 shares. Based on an average trading volume of 26,300 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the company's stock are sold short.June 30, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by William BlairWilliam Blair reissued an "outperform" rating on shares of Barinthus Biotherapeutics in a research note on Thursday.June 13, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $3.00 Price Target at BarclaysBarclays reduced their price objective on Barinthus Biotherapeutics from $7.00 to $3.00 and set an "overweight" rating on the stock in a research note on Thursday.June 13, 2024 | marketbeat.comBarinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus InfectionsJune 12, 2024 | globenewswire.comBarinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis BJune 6, 2024 | globenewswire.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 52.1% in MayBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 9,100 shares, a decrease of 52.1% from the April 30th total of 19,000 shares. Based on an average daily trading volume, of 22,300 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the company's shares are short sold.May 29, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of Barinthus Biotherapeutics in a report on Thursday.May 16, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Barinthus Biotherapeutics plc Issued By William Blair (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - Equities research analysts at William Blair raised their Q2 2024 earnings per share (EPS) estimates for Barinthus Biotherapeutics in a report issued on Monday, May 13th. William Blair analyst A. Hsieh now forecasts that the company willMay 16, 2024 | marketbeat.comBRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024May 13, 2024 | investorplace.comBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate DevelopmentsMay 13, 2024 | globenewswire.comIncreases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)May 4, 2024 | finance.yahoo.comBarinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical OfficerMay 1, 2024 | globenewswire.comBarinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Up 39.6% in AprilBarinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 14,100 shares, an increase of 39.6% from the March 31st total of 10,100 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average trading volume of 22,000 shares, the short-interest ratio is currently 0.6 days.April 27, 2024 | marketbeat.comInfection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed PerspectivesApril 19, 2024 | markets.businessinsider.comBarinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) InfectionsApril 18, 2024 | globenewswire.comShort Interest in Barinthus Biotherapeutics plc (NASDAQ:BRNS) Drops By 15.1%Barinthus Biotherapeutics plc (NASDAQ:BRNS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 10,100 shares, a decrease of 15.1% from the March 15th total of 11,900 shares. Based on an average daily trading volume, of 21,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company's stock are short sold.April 14, 2024 | marketbeat.comBRNS Barinthus Biotherapeutics plcApril 14, 2024 | seekingalpha.comBarinthus Biotherapeutics Reports Significant Financial Shifts and Clinical Progress in 2023March 22, 2024 | finance.yahoo.comWilliam Blair Comments on Barinthus Biotherapeutics plc's Q1 2025 Earnings (NASDAQ:BRNS)Barinthus Biotherapeutics plc (NASDAQ:BRNS - Free Report) - William Blair issued their Q1 2025 EPS estimates for shares of Barinthus Biotherapeutics in a report released on Wednesday, March 20th. William Blair analyst A. Hsieh forecasts that the company will post earnings per share of ($0.71) forMarch 22, 2024 | marketbeat.comBarinthus Biotherapeutics (NASDAQ:BRNS) Given New $8.00 Price Target at HC WainwrightHC Wainwright decreased their target price on shares of Barinthus Biotherapeutics from $15.00 to $8.00 and set a "buy" rating on the stock in a research report on Thursday.March 21, 2024 | marketbeat.comBarinthus Biotherapeutics: Q4 Earnings InsightsMarch 20, 2024 | benzinga.comBarinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate DevelopmentsMarch 20, 2024 | globenewswire.com Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk’s new company could top a trillion? (Ad)The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. BRNS Media Mentions By Week BRNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRNS News Sentiment▼-1.000.48▲Average Medical News Sentiment BRNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRNS Articles This Week▼01▲BRNS Articles Average Week Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IFRX News Today SAVA News Today VXRT News Today SGMT News Today FTLF News Today PBYI News Today APLT News Today IPHA News Today ELUT News Today NBTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BRNS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts